Inhibition of human platelet function in vivo with a monoclonal antibody. With observations on the newly dead as experimental subjects.
| Autor: | Coller, Barry S., Scudder, Lesley E., Berger, Harvey J., Iuliucci, John D., Coller, B S, Scudder, L E, Berger, H J, Iuliucci, J D |
|---|---|
| Předmět: |
PLATELET glycoprotein GPIIb-IIIa complex
HEMODYNAMICS ADENOSINE diphosphate BLOOD coagulation BLOOD platelets BRAIN death COLLAGEN COMPARATIVE studies GLYCOPROTEINS IMMUNITY IMMUNOGLOBULINS RESEARCH methodology MEDICAL cooperation MEDICAL research MONOCLONAL antibodies RESEARCH INSTITUTIONAL review boards EVALUATION research PLATELET aggregation inhibitors CHEMICAL inhibitors |
| Zdroj: | Annals of Internal Medicine; 10/15/88, Vol. 109 Issue 8, p635-638, 4p, 1 Chart, 1 Graph |
| Abstrakt: | The F(ab')2 fragment of a monoclonal antibody to the platelet glycoprotein IIb/IIIa receptor (7E3) is a potent inhibitor of both in-vitro platelet aggregation and in-vivo platelet thrombus formation in animal studies. As a first step in assessing the potential of 7E3-F(ab')2 as an antithrombotic agent for use in humans, we administered 7E3-F(ab')2 intravenously at increasing doses to a person who had just died and was being maintained on a respirator (neomort). At 0.1 and at 0.2 mg/kg body weight, 74% and 92% of the glycoprotein IIb/IIIa receptors were blocked, respectively; adenosine-diphosphate-induced platelet aggregation was inhibited by 84% and 100% at these same doses. Platelet glycoprotein Ib function remained intact, even at 0.6 mg/kg. Acute hemodynamic or hemorrhagic toxicity was not noted. This antibody fragment, a potent, immediate-acting inhibitor of platelet aggregation, may be of benefit in vaso-occlusive and thromboembolic disorders. [ABSTRACT FROM AUTHOR] |
| Databáze: | Complementary Index |
| Externí odkaz: |
|